Caris Molecular Tumor Board

The Caris Molecular Tumor Board provides oncologists with the opportunity to interact with leading cancer experts from across the country to obtain interpretation of molecular findings and therapeutic guidance for individual patients.

Collaborative Cancer Treatment

The Caris Molecular Tumor Board (CMTB), provides oncologists with the opportunity to interact with leading cancer experts from across the country to obtain interpretation of molecular findings and therapeutic guidance for individual patients. This proprietary virtual tumor board platform is an innovative, real-time approach to deciphering complex data and treatment decisions on difficult-to-treat cases. The efficient access to cutting-edge information provided by the Caris Molecular Tumor Board allows oncologists to focus their efforts on what matters most – developing the most informed personalized treatment strategies for their patients.

CMTB Platform

Our platform facilitates asynchronous discussions to collaborate more efficiently on patient cases while providing:

  • Collaboration – Specialists from different institutions working together to ensure the appropriate diagnostic tests and treatment options are being considered for your patients
  • Expert Review & Interpretation – Streamlined process allows each patient case submitted to be personally evaluated and discussed by members of the Caris Molecular Tumor Board
  • Broad Review of Treatment Options – Reviews beyond the standard of care therapies, with recommendations that could include FDA-approved treatments, clinical trials of matched targeted therapies, and additional tumor or germline genetic testing options
  • Accelerated Review Time – Each patient case submitted is typically reviewed within 7 days, with a physician signed report summary released following case conclusion
  • Virtual Platform – Allows oncologists to post and review patient medical records and other patient data from different parts of the country while allowing their patients to be treated within their own community

Submit a case for review

To submit a case for review, visit the CMTB Portal and select “Quick Submit.”

Caris Molecular Tumor Board Case Study

The CMTB works one on one with oncologists to obtain interpretation of molecular findings and therapeutic guidance on difficult-to-treat cases. Read how the CMTB approached a patient diagnosed with Stage IV cecal cancer with liver and mesenteric metastases.

Background: While the diagnosis of Stage IV colon cancer can be devastating, the revelations of the tumor’s molecular vulnerabilities can offer effective therapeutic opportunities and pave a clear path for the treatment plan to the best outcome. This requires thorough interrogation of the patient’s tumor for a complete landscape of the molecular features and interpretation of the molecular information from a multidisciplinary expert group.

Expert Board Members

Our panel of experts come from many of the leading cancer institutions in the world today to review every case and provide individualized diagnostic and therapeutic evaluations for each patient.

Questions?

If you have questions about Caris molecular profiling please contact us today.